[Clinical effect of Vinorelbine monotherapy in 18 cases of advanced or metastatic breast cancer].
We analyzed the efficacy and safety of Vinorelbine monotherapy in 18 patients with advanced or metastatic breast cancer between May 2006 and July 2007, retrospectively. The outcomes were PR in 4 cases, long-term SD in 1, SD in 5, and PD in 8. The overall response rate was 22.2%(4/18), and a clinical benefit was shown in 27.8%(5/18). The median time to progression(TTP)was 138 days. Major adverse events were leukopenia(72.2%), neutropenia(77.8%) and superficial phlebitis(58.8%). These results suggest that Vinorelbine was a safe and effective agent.
Sasada
Shinsuke
S
Department of Breast and Endocrine Surgery, Hiroshima City Hospital.
Ohtani
Shoichiro
S
Kim
Ryuji
R
Higaki
Kenji
K
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D015996:Survival Rate; D016896:Treatment Outcome; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine